BBOT's Pan-KRAS Inhibitor BBO-11818 Shows Robust Anti-Tumor Activity in Preclinical Models
Summary
BridgeBio Oncology Therapeutics (BBOT) announced positive preclinical data for its pan-KRAS inhibitor, BBO-11818, presented at the AACR Annual Meeting 2026. The data demonstrated robust anti-tumor activity in KRAS-mutant preclinical models, targeting both ON and OFF states of KRAS. This news builds on the company's recent momentum, following the FDA Fast Track Designation for its investigational drug BBO-1181 earlier this week. The strong preclinical results for BBO-11818, which is already in Phase 1 clinical trials, underscore its potential to address a significant unmet need in various KRAS-mutant cancers. While BridgeBio Pharma (BBIO) is also listed, this news is primarily focused on BBOT's specific drug development. Traders will be watching for updated Phase 1 clinical data, which is anticipated in the second half of 2026, as the next key catalyst for this promising asset.
At the time of this announcement, BBOT was trading at $8.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $709.9M. The 52-week trading range was $8.08 to $14.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.